HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 01.wnl.0000280576.73609.c6v1 70/13_Part_2/1079    most recent Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tintoré, M. Articles by Montalban, X. Search for Related Content PubMed PubMed Citation Articles by Tintoré, M. Articles by Montalban, X. Related Collections MRI All Immunology Autoimmune diseases Prognosis Optic nerve Diplopia (double vision) Cerebrospinal Fluid All Demyelinating disease (CNS) Multiple sclerosis Optic neuritis; see Neuro-ophthalmology/Optic Nerve Transverse myelitis Cohort studies Natural history studies (prognosis)

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

From CENTRE: Unit of Clinical Neuroimmunology (Department of Neurology) (M.T., J.R., C.T., R.P., C.N., N.T., H.P., M.C., J.S.-G., X.M.), Magnetic Resonance Unit (Department of Radiology) (A.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

Address correspondence and reprint requests to Dr. Mar Tintoré, Unitat de Neuroimmunologia Clinica (UNIC), Edif. Escola d'infermeria planta 2, Hospital Universitari Vall d'Hebron, Pg Vall d'Hebron 119-129, 08035 Barcelona, Spain mtintore{at}vhebron.net

Background: To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS).

Methods: From 1995 to 2006, 572 patients with CIS were included in a prospective study. Patients underwent brain MRI and determination of OB within 3 months of first attack. The number and location of lesions and presence of OB were studied. We analyzed time to second attack and to Expanded Disability Status Scale 3.0 according to number of Barkhof criteria (BC) and the presence or absence of OB.

Results: We studied 415 (73%) patients with CIS with both baseline MRI and determination of OB. Patients were followed for a mean of 50 months (SD 31). Compared to the reference group with 0 BC at baseline MRI, patients with one to two BC showed a hazard ratio (HR) for conversion to CDMS of 3.8 (2.0 to 7.2) and patients with three to four BC of 8.9 (4.8 to 16.4). Of the total cohort, OB were positive in 61% of the patients. However, broken down by MRI group, OB were positive in 31% of those with no BC; 69% of those with one to two BC; and 85% of those with three or four BC. The presence of OB increased the risk of a second relapse (HR 1.7; 1.1 to –2.7) independently of baseline MRI but did not modify the development of disability.

Conclusions: Presence of oligoclonal bands doubles the risk for having a second attack, independently of MRI, but does not seem to influence the development of disability.

GLOSSARY: BC = Barkhof criteria; CDMS = clinically definite multiple sclerosis; CIS = clinically isolated syndromes; EDSS = Expanded Disability Status Scale; HR = hazard ratio; MS = multiple sclerosis; OB = oligoclonal bands.

Editorial, page 1059

e-Pub ahead of print on September 19, 2007, at www.neurology.org.

Disclosure: The authors' unit has received research grants from the following companies: Bayer-Shering AG, Biogen-Idec, Sanofi-Aventis, Merck-Serono, and Teva. Mar Tintore, Jordi Rio, and Xavier Montalban have received scientific honoraria and travel expenses from all companies mentioned. Alex Rovira, Carmen Tur, Raúl Pelayo, Carlos Nos, Neus Téllez, Hector Perkal, Manuel Comabella, and Jaume Sastre-Garriga have no conflicts of interest. No financial support was received for the present study.

Received March 28, 2007. Accepted in final form July 3, 2007.

This article has been cited by other articles:

				O. Garcea, A. Villa, F. Caceres, T. Adoni, M. Alegria, R. Barbosa Thomaz, R. Buzo, L. Llamas Lopez, and M. Rivera Kindel Early treatment of multiple sclerosis: a Latin American Experts Meeting Multiple Sclerosis, October 1, 2009; 15(3_suppl): S1 - S12. [Abstract] [PDF]

				A Siva, S Saip, A Altintas, A Jacob, B. Keegan, and O. Kantarci Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease Multiple Sclerosis, August 1, 2009; 15(8): 918 - 927. [Abstract] [PDF]

				M Hutchinson Predicting and preventing the future: actively managing multiple sclerosis Practical Neurology, June 1, 2009; 9(3): 133 - 143. [Abstract] [Full Text] [PDF]

				Oligoclonal Bands and MRI in First Attack of Multiple Sclerosis Journal Watch Neurology, June 17, 2008; 2008(617): 2 - 2. [Full Text]

				R. Q. Hintzen and G. Giovannoni CSF analysis in suspected MS: Do bands aid? Neurology, March 25, 2008; 70(13_Part_2): 1059 - 1060. [Full Text] [PDF]